{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:15:53Z","timestamp":1787584553722,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amgen Europe GmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To predict the real-world (RW) cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in relapsed multiple myeloma (MM) patients after one to three prior therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A partitioned survival model that included three health states (progression-free, progressed disease and death) was built. Progression-free survival (PFS), overall survival (OS) and time to discontinuation (TTD) data for the Rd arm were derived using the Registry of Monoclonal Gammopathies in the Czech Republic; the relative treatment effects of KRd versus Rd were estimated from the phase 3, randomised, ASPIRE trial, and were used to predict PFS, OS and TTD for KRd. The model was developed from the payer perspective and included drug costs, administration costs, monitoring costs, palliative care costs and adverse-event related costs collected from Czech sources.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The base case incremental cost effectiveness ratio for KRd compared with Rd was \u20ac73,156 per quality-adjusted life year (QALY) gained. Patients on KRd incurred costs of \u20ac117,534 over their lifetime compared with \u20ac53,165 for patients on Rd. The QALYs gained were 2.63 and 1.75 for patients on KRd and Rd, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combining the strengths of randomised controlled trials and observational databases in cost-effectiveness models can generate policy-relevant results to allow well-informed decision-making. The current model showed that KRd is likely to be cost-effective versus Rd in the RW and, therefore, the reimbursement of KRd represents an efficient allocation of resources within the healthcare system.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10198-019-01122-6","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T08:53:16Z","timestamp":1572511996000},"page":"219-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data"],"prefix":"10.1007","volume":"21","author":[{"given":"M.","family":"Campioni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Agirrezabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Minarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Spicka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gonzalez-McQuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Jandova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Maisnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"1122_CR1","doi-asserted-by":"crossref","unstructured":"American Society of Clinical Oncology (ASCO): Multiple Myeloma: Statistics. https:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/statistics (2016). Accessed 22 Nov 2017","DOI":"10.1158\/1078-0432.CCR-16-0184"},{"issue":"20","key":"1122_CR2","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1182\/blood-2014-07-552059","volume":"124","author":"B Barlogie","year":"2014","unstructured":"Barlogie, B., Mitchell, A., van Rhee, F., Epstein, J., Morgan, G.J., Crowley, J.: Curing myeloma at last: defining criteria and providing the evidence. Blood 124(20), 3043\u20133051 (2014). https:\/\/doi.org\/10.1182\/blood-2014-07-552059","journal-title":"Blood"},{"issue":"5","key":"1122_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D., Bray, F.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359\u2013E386 (2015). https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int. J. Cancer"},{"issue":"11","key":"1122_CR4","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1038\/bjc.2016.77","volume":"114","author":"M Laudicella","year":"2016","unstructured":"Laudicella, M., Walsh, B., Burns, E., Smith, P.C.: Cost of care for cancer patients in England: evidence from population-based patient-level data. Br. J. Cancer 114(11), 1286\u20131292 (2016). https:\/\/doi.org\/10.1038\/bjc.2016.77","journal-title":"Br. J. Cancer"},{"key":"1122_CR5","unstructured":"National Cancer Institute\u2019s Division of Cancer Control and Population Sciences: Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"issue":"10","key":"1122_CR6","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s1470-2045(11)70141-3","volume":"12","author":"R Sullivan","year":"2011","unstructured":"Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N.J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I.F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J.G., Purushotham, A.D., Naredi, P., Eggermont, A., Brennan, M.F., Steinberg, M.L., De Ridder, M., McCloskey, S.A., Verellen, D., Roberts, T., Storme, G., Hicks, R.J., Ell, P.J., Hirsch, B.R., Carbone, D.P., Schulman, K.A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N.G., Meltzer, D., Kerr, D., Aapro, M.: Delivering affordable cancer care in high-income countries. Lancet Oncol. 12(10), 933\u2013980 (2011). https:\/\/doi.org\/10.1016\/s1470-2045(11)70141-3","journal-title":"Lancet Oncol."},{"issue":"8","key":"1122_CR7","doi-asserted-by":"publisher","first-page":"831","DOI":"10.18553\/jmcp.2017.23.8.831","volume":"23","author":"Y Chen","year":"2017","unstructured":"Chen, Y., Lairson, D.R., Chan, W., Huo, J., Du, X.L.: Cost-effectiveness of novel agents in medicare patients with multiple myeloma: findings from a US payer\u2019s perspective. J. Manag. Care Spec Pharm. 23(8), 831\u2013843 (2017). https:\/\/doi.org\/10.18553\/jmcp.2017.23.8.831","journal-title":"J. Manag. Care Spec Pharm."},{"issue":"Suppl 1","key":"1122_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1634\/theoncologist.2010-S1-58","volume":"15","author":"CD Mullins","year":"2010","unstructured":"Mullins, C.D., Montgomery, R., Tunis, S.: Uncertainty in assessing value of oncology treatments. Oncologist 15(Suppl 1), 58\u201364 (2010). https:\/\/doi.org\/10.1634\/theoncologist.2010-S1-58","journal-title":"Oncologist"},{"issue":"2","key":"1122_CR9","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.healthpol.2012.04.014","volume":"106","author":"M Neyt","year":"2012","unstructured":"Neyt, M., Cleemput, I., Thiry, N., De Laet, C.: Calculating an intervention\u2019s (cost-)effectiveness for the real-world target population: the potential of combining strengths of both RCTs and observational data. Health Policy (Amst Neth) 106(2), 207\u2013210 (2012). https:\/\/doi.org\/10.1016\/j.healthpol.2012.04.014","journal-title":"Health Policy (Amst Neth)"},{"issue":"8","key":"1122_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40273-013-0061-6","volume":"31","author":"CW van Gils","year":"2013","unstructured":"van Gils, C.W., de Groot, S., Redekop, W.K., Koopman, M., Punt, C.J., Uyl-de Groot, C.A.: Real-world cost-effectiveness of oxaliplatin in stage III colon cancer: a synthesis of clinical trial and daily practice evidence. PharmacoEconomics 31(8), 703\u2013718 (2013). https:\/\/doi.org\/10.1007\/s40273-013-0061-6","journal-title":"PharmacoEconomics"},{"issue":"14","key":"1122_CR11","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N.J., Usmani, S.Z., Rabin, N., Orlowski, R.Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.S., Ben Yehuda, D., Richardson, P.G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N.Z., O\u2019Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., Moreau, P.: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319\u20131331 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N. Engl. J. Med."},{"key":"1122_CR12","doi-asserted-by":"crossref","unstructured":"Hajek, R., Jarkovsky, J., Campioni, M., DeCosta, L., Treur, M., Gonzalez-McQuire, S., Bouwmeester, W.: Long-term outcomes and treatment patterns in patients with symptomatic multiple myeloma in the real-world setting: a retrospective analysis of the Czech RMG Registry. PCN136. Paper presented at the International Society for Pharmacoeconomics and Outcomes Research 21st Annual Meeting, Washington, DC, US, 21\u201325 May (2016)","DOI":"10.1016\/j.jval.2016.03.1470"},{"issue":"7","key":"1122_CR13","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Rollig, C., Einsele, H., Wu, K.L., Singhal, A., San-Miguel, J., Matsumoto, M., Katz, J., Bleickardt, E., Poulart, V., Anderson, K.C., Richardson, P.: Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621\u2013631 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1505654","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"1122_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P., Masszi, T., Grzasko, N., Bahlis, N.J., Hansson, M., Pour, L., Sandhu, I., Ganly, P., Baker, B.W., Jackson, S.R., Stoppa, A.M., Simpson, D.R., Gimsing, P., Palumbo, A., Garderet, L., Cavo, M., Kumar, S., Touzeau, C., Buadi, F.K., Laubach, J.P., Berg, D.T., Lin, J., Di Bacco, A., Hui, A.M., van de Velde, H., Richardson, P.G.: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374(17), 1621\u20131634 (2016). https:\/\/doi.org\/10.1056\/NEJMoa1516282","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"1122_CR15","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., Masszi, T., Spicka, I., Oriol, A., Hajek, R., Rosinol, L., Siegel, D.S., Mihaylov, G.G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A.J., San-Miguel, J.F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W.I., Mateos, M.V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M.E., Yang, X., Xing, B., Moreau, P., Palumbo, A.: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142\u2013152 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1411321","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"1122_CR16","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1182\/blood.V126.23.5414.5414","volume":"126","author":"J Radocha","year":"2015","unstructured":"Radocha, J., Pour, L., Spicka, I., Scudla, V., Gregora, E., Frankova, H., Hajek, R., Schutzova, M., Sykora, M., Kessler, P., Adamova, D., Wrobel, M., Sedlarikova, L., Sevcikova, S., Horinek, D., Pelcova, J., Brozova, L., Jarkovsky, J., Maisnar, V.: Registry of monoclonal gammopathies (RMG) in the Czech Republic. Blood 126(23), 5414 (2015)","journal-title":"Blood"},{"issue":"6","key":"1122_CR17","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1177\/0272989x13492018","volume":"33","author":"R Grieve","year":"2013","unstructured":"Grieve, R., Hawkins, N., Pennington, M.: Extrapolation of survival data in cost-effectiveness analyses: improving the current state of play. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 33(6), 740\u2013742 (2013). https:\/\/doi.org\/10.1177\/0272989x13492018","journal-title":"Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak."},{"issue":"4","key":"1122_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0272989x16639900","volume":"37","author":"C Jackson","year":"2017","unstructured":"Jackson, C., Stevens, J., Ren, S., Latimer, N., Bojke, L., Manca, A., Sharples, L.: Extrapolating survival from randomized trials using external data: a review of methods. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 37(4), 377\u2013390 (2017). https:\/\/doi.org\/10.1177\/0272989x16639900","journal-title":"Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak."},{"issue":"4","key":"1122_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0272989x16670604","volume":"37","author":"P Guyot","year":"2017","unstructured":"Guyot, P., Ades, A.E., Beasley, M., Lueza, B., Pignon, J.P., Welton, N.J.: Extrapolation of survival curves from cancer trials using external information. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 37(4), 353\u2013366 (2017). https:\/\/doi.org\/10.1177\/0272989x16670604","journal-title":"Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak."},{"issue":"6","key":"1122_CR20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1177\/0272989x12472398","volume":"33","author":"NR Latimer","year":"2013","unstructured":"Latimer, N.R.: Survival analysis for economic evaluations alongside clinical trials\u2013extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak. 33(6), 743\u2013754 (2013). https:\/\/doi.org\/10.1177\/0272989x12472398","journal-title":"Med. Decis. Mak. Int. J. Soc. Med. Decis. Mak."},{"issue":"8","key":"1122_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1634\/theoncologist.2015-0006","volume":"20","author":"SC Seferina","year":"2015","unstructured":"Seferina, S.C., Lobbezoo, D.J., de Boer, M., Dercksen, M.W., van den Berkmortel, F., van Kampen, R.J., van de Wouw, A.J., de Vries, B., Joore, M.A., Peer, P.G., Voogd, A.C., Tjan-Heijnen, V.C.: Real-life use and effectiveness of adjuvant trastuzumab in early breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Oncologist 20(8), 856\u2013863 (2015). https:\/\/doi.org\/10.1634\/theoncologist.2015-0006","journal-title":"Oncologist"},{"key":"1122_CR22","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16985","author":"SC Seferina","year":"2017","unstructured":"Seferina, S.C., Ramaekers, B.L., de Boer, M., Dercksen, M.W., van den Berkmortel, F., van Kampen, R.J., van de Wouw, A.J., Voogd, A.C., Tjan Heijnen, V.C., Joore, M.A.: Cost and cost-effectiveness of adjuvant trastuzumab in the real world setting: a study of the Southeast Netherlands Breast Cancer Consortium. Oncotarget (2017). https:\/\/doi.org\/10.18632\/oncotarget.16985","journal-title":"Oncotarget"},{"key":"1122_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1471-2466-10-47","volume":"10","author":"M Neyt","year":"2010","unstructured":"Neyt, M., Devriese, S., Thiry, N., Van den Bruel, A.: Tiotropium\u2019s cost-effectiveness for the treatment of COPD: a cost-utility analysis under real-world conditions. BMC Pulm. Med. 10, 47 (2010). https:\/\/doi.org\/10.1186\/1471-2466-10-47","journal-title":"BMC Pulm. Med."},{"key":"1122_CR24","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejca.2017.01.027","volume":"79","author":"RJW van Kampen","year":"2017","unstructured":"van Kampen, R.J.W., Ramaekers, B.L.T., Lobbezoo, D.J.A., de Boer, M., Dercksen, M.W., van den Berkmortel, F., Smilde, T.J., van de Wouw, A.J., Peters, F.P.J., van Riel, J.M.G., Peters, N., Tjan-Heijnen, V.C.G., Joore, M.A.: Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Eur. J. Cancer (Oxf. Engl. 1990) 79, 238\u2013246 (2017). https:\/\/doi.org\/10.1016\/j.ejca.2017.01.027","journal-title":"Eur. J. Cancer (Oxf. Engl. 1990)"},{"issue":"10","key":"1122_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/jamacardio.2017.2762","volume":"2","author":"GC Fonarow","year":"2017","unstructured":"Fonarow, G.C., Keech, A.C., Pedersen, T.R., Giugliano, R.P., Sever, P.S., Lindgren, P., van Hout, B., Villa, G., Qian, Y., Somaratne, R., Sabatine, M.S.: Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2(10), 1069\u20131078 (2017). https:\/\/doi.org\/10.1001\/jamacardio.2017.2762","journal-title":"JAMA Cardiol."},{"issue":"6","key":"1122_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1080\/13696998.2017.1284078","volume":"20","author":"PP Toth","year":"2017","unstructured":"Toth, P.P., Danese, M., Villa, G., Qian, Y., Beaubrun, A., Lira, A., Jansen, J.P.: Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context. J. Med. Econ. 20(6), 555\u2013564 (2017). https:\/\/doi.org\/10.1080\/13696998.2017.1284078","journal-title":"J. Med. Econ."},{"key":"1122_CR27","unstructured":"National Institute for Health and Care Excellence: Multiple myeloma\u2014lenalidomide (post bortezomib) (part rev TA171) [ID667]. http:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag452\/documents (2014). Accessed 22 Jan 2018"},{"issue":"6","key":"1122_CR28","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/j.1600-0609.2010.01526.x","volume":"85","author":"J Hornberger","year":"2010","unstructured":"Hornberger, J., Rickert, J., Dhawan, R., Liwing, J., Aschan, J., Lothgren, M.: The cost-effectiveness of bortezomib in relapsed\/refractory multiple myeloma: swedish perspective. Eur. J. Haematol. 85(6), 484\u2013491 (2010). https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01526.x","journal-title":"Eur. J. Haematol."},{"key":"1122_CR29","unstructured":"National Institute for Health and Care Excellence: Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib. Technology appraisal guidance [TA338]. https:\/\/www.nice.org.uk\/guidance\/ta338 (2015). Accessed 23 Jan 2018"},{"key":"1122_CR30","unstructured":"National Institute for Health and Care Excellence: Panobinostat for treating multiple myeloma after at least 2 previous treatments. Technology appraisal guidance [TA380]. https:\/\/www.nice.org.uk\/guidance\/ta380\/history (2016). Accessed 23 Jan 2018"},{"issue":"3","key":"1122_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3111\/13696998.2015.1115407","volume":"19","author":"SZ Usmani","year":"2016","unstructured":"Usmani, S.Z., Cavenagh, J.D., Belch, A.R., Hulin, C., Basu, S., White, D., Nooka, A., Ervin-Haynes, A., Yiu, W., Nagarwala, Y., Berger, A., Pelligra, C.G., Guo, S., Binder, G., Gibson, C.J., Facon, T.: Cost-effectiveness of lenalidomide plus dexamethasone vs bortezomib plus melphalan and prednisone in transplant-ineligible U.S. patients with newly-diagnosed multiple myeloma. J. Med. Econ. 19(3), 243\u2013258 (2016). https:\/\/doi.org\/10.3111\/13696998.2015.1115407","journal-title":"J. Med. Econ."},{"issue":"11","key":"1122_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1080\/13696998.2016.1194278","volume":"19","author":"AJ Jakubowiak","year":"2016","unstructured":"Jakubowiak, A.J., Campioni, M., Benedict, A., Houisse, I., Tichy, E., Giannopoulou, A., Aggarwal, S.K., Barber, B.L., Panjabi, S.: Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective. J. Med. Econ. 19(11), 1061\u20131074 (2016). https:\/\/doi.org\/10.1080\/13696998.2016.1194278","journal-title":"J. Med. Econ."},{"issue":"12","key":"1122_CR33","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1080\/17474086.2017.1391088","volume":"10","author":"AJ Jakubowiak","year":"2017","unstructured":"Jakubowiak, A.J., Houisse, I., Majer, I., Benedict, A., Campioni, M., Panjabi, S., Ailawadhi, S.: Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States. Expert Rev. Hematol. 10(12), 1107\u20131119 (2017). https:\/\/doi.org\/10.1080\/17474086.2017.1391088","journal-title":"Expert Rev. Hematol."},{"key":"1122_CR34","unstructured":"Amgen, Data on File.Treatment utilization: a retrospective analysis of the Czech RMG registry. 2018"},{"key":"1122_CR35","unstructured":"European Medicines Agency: Kyprolis. Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003790\/WC500197692.pdf . Accessed 4 Aug 2017"},{"key":"1122_CR36","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: Spr\u00e1vn\u00ed \u0159\u00edzen\u00ed. sp. zn. SUKLS157419\/2013 (LP Velcade). https:\/\/verso.sukl.cz\/fcgi\/verso.fpl?fname=vp_fspis (2013). Accessed 12 Dec 2017"},{"key":"1122_CR37","unstructured":"European Medicines Agency: Revlimid. Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000717\/WC500056018.pdf . Accessed 4 Aug 2017"},{"key":"1122_CR38","doi-asserted-by":"crossref","unstructured":"Stewart, A.K., Siegel, D.S., Ludwig, H., Facon, T., Goldschmidt, H., Jakubowiak, A.J., San-Miguel, J.F., Obreja, M., Blaedel, J., Dimopoulos, M.A.: 743 Overal Survival (OS) of Patients with Relapsed\/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide and Dexamethasone (Rd): Final Analysis from the Randomized Phase 3 Aspire Trial. Paper presented at the American Society of Hematology (ASH). 59th Annual Meeting & Exposition, Atlanta, GA. December 9\u201312 (2017)","DOI":"10.1182\/blood.V130.Suppl_1.743.743"},{"issue":"6","key":"1122_CR39","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/(SICI)1097-0258(19970330)16:6<611::AID-SIM437>3.0.CO;2-T","volume":"16","author":"NH Ng\u2019andu","year":"1997","unstructured":"Ng\u2019andu, N.H.: An empirical comparison of statistical tests for assessing the proportional hazards assumption of Cox\u2019s model. Stat. Med. 16(6), 611\u2013626 (1997)","journal-title":"Stat. Med."},{"key":"1122_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/0470856289","volume-title":"Statistical analysis of cost-effectiveness data","author":"AR Willan","year":"2006","unstructured":"Willan, A.R., Briggs, A.H.: Statistical analysis of cost-effectiveness data. Wiley, England (2006)"},{"key":"1122_CR41","unstructured":"European Central Bank: Czech koruna (CZK). https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/euro_reference_exchange_rates\/html\/eurofxref-graph-czk.en.html (2017). Accessed 11 Dec 2017"},{"key":"1122_CR42","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: List of reimbursed medicinal products valid as of 1.12.2017. http:\/\/www.sukl.eu\/sukl\/list-of-reimbursed-medicinal-products-valid-as-of-1-12-2017 (2017). Accessed 12 Dec 2017"},{"issue":"3","key":"1122_CR43","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-008-0018-1","volume":"114","author":"I Chirivella","year":"2009","unstructured":"Chirivella, I., Bermejo, B., Insa, A., Perez-Fidalgo, A., Magro, A., Rosello, S., Garcia-Garre, E., Martin, P., Bosch, A., Lluch, A.: Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients. Breast Cancer Res. Treat. 114(3), 479\u2013484 (2009). https:\/\/doi.org\/10.1007\/s10549-008-0018-1","journal-title":"Breast Cancer Res. Treat."},{"issue":"5","key":"1122_CR44","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.3747\/co.20.1394","volume":"20","author":"TE Delea","year":"2013","unstructured":"Delea, T.E., Amdahl, J., Chit, A., Amonkar, M.M.: Cost-effectiveness of lapatinib plus letrozole in her2-positive, hormone receptor-positive metastatic breast cancer in Canada. Curr. Oncol. (Toronto Ont.) 20(5), e371\u2013e387 (2013). https:\/\/doi.org\/10.3747\/co.20.1394","journal-title":"Curr. Oncol. (Toronto Ont.)"},{"issue":"4","key":"1122_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40273-016-0474-0","volume":"35","author":"K Fust","year":"2017","unstructured":"Fust, K., Li, X., Maschio, M., Villa, G., Parthan, A., Barron, R., Weinstein, M.C., Somers, L., Hoefkens, C., Lyman, G.H.: Cost-Effectiveness analysis of prophylaxis treatment strategies to reduce the incidence of febrile neutropenia in patients with early-stage breast cancer or non-Hodgkin lymphoma. PharmacoEconomics 35(4), 425\u2013438 (2017). https:\/\/doi.org\/10.1007\/s40273-016-0474-0","journal-title":"PharmacoEconomics"},{"issue":"12","key":"1122_CR46","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/jco.1990.8.12.1935","volume":"8","author":"WM Hryniuk","year":"1990","unstructured":"Hryniuk, W.M., Goodyear, M.: The calculation of received dose intensity. J. Clin. Oncol. 8(12), 1935\u20131937 (1990). https:\/\/doi.org\/10.1200\/jco.1990.8.12.1935","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"1122_CR47","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1200\/jop.2012.000810","volume":"9","author":"KL Vavra","year":"2013","unstructured":"Vavra, K.L., Saadeh, C.E., Rosen, A.L., Uptigrove, C.E., Srkalovic, G.: Improving the relative dose intensity of systemic chemotherapy in a community-based outpatient cancer center. J. Oncol. Pract. 9(5), e203\u2013e211 (2013). https:\/\/doi.org\/10.1200\/jop.2012.000810","journal-title":"J. Oncol. Pract."},{"key":"1122_CR48","unstructured":"Czech Myeloma Group: Czech Myeloma Group guidelines for the treatment of multiple myeloma. http:\/\/www.myeloma.cz\/index.php?pg=mnohocetny-myelom\u2013guidelines (2017)"},{"key":"1122_CR49","unstructured":"Ministerstvo vnitra: Vyhl\u00e1\u0161ka \u010d. 421\/2016 Sb., kterou se m\u011bn\u00ed vyhl\u00e1\u0161ka Ministerstva zdravotnictv\u00ed \u010d. 134\/1998 Sb., kterou se vyd\u00e1v\u00e1 seznam zdravotn\u00edch v\u00fdkon\u016f s bodov\u00fdmi hodnotami, ve zn\u011bn\u00ed pozd\u011bj\u0161\u00edch p\u0159edpis\u016f. https:\/\/szv.mzcr.cz\/Vyhlaska . Accessed 12 Dec 2017"},{"key":"1122_CR50","unstructured":"V\u0161eobecn\u00e1 zdravotn\u00ed poji\u0161\u0165ovna \u010cesk\u00e9 republiky (VZP \u010cR): \u010c\u00edseln\u00edk 984. https:\/\/www.vzp.cz\/poskytovatele\/ciselniky\/individualne-pripravovane-lecive-pripravky-a-vyrobky-transfuznich-stanic-a-radiofarmaka\/archiv . Accessed 12 Dec 2017"},{"key":"1122_CR51","unstructured":"Novartis: Panobinostat for treating multiple myeloma in people who have received at least one prior therapy. ID663 Single technology appraisal (STA) manufacturer\u2019s submission. http:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-tag477\/documents (2015). Accessed 15 Nov 2015"},{"key":"1122_CR52","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: Spr\u00e1vn\u00ed \u0159\u00edzen\u00ed. sp. zn. SUKLS58379\/2014 (LP Imnovid). https:\/\/verso.sukl.cz\/fcgi\/verso.fpl?fname=vp_fspis (2014). Accessed 12 Dec 2017"},{"key":"1122_CR53","unstructured":"Ministerstvo zdravotnictv\u00ed: Metodick\u00e9 materi\u00e1ly pro rok 2017. Materi\u00e1ly dle Sd\u011blen\u00ed \u010cS\u00da \u010d. 313\/2016 Sb., o aktualizaci Klasifikace hospitalizovan\u00fdch (IR-DRG). http:\/\/www.mzcr.cz\/Odbornik\/dokumenty\/metodicke-materialy-pro-rok-2017_12858_1058_3.html . Accessed 10 Oct 2017"},{"key":"1122_CR54","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: Postup pro posuzov\u00e1n\u00ed anal\u00fdzy n\u00e1kladov\u00e9 efektivity (SP-CAU-028-W). http:\/\/www.sukl.cz\/file\/85788_1_1 (2017). Accessed 12 Dec 2017"},{"issue":"3","key":"1122_CR55","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s10198-012-0395-6","volume":"14","author":"RE Brown","year":"2013","unstructured":"Brown, R.E., Stern, S., Dhanasiri, S., Schey, S.: Lenalidomide for multiple myeloma: cost-effectiveness in patients with one prior therapy in England and Wales. Eur. J. Health Econ. HEPAC Health Econ. Prev. Care 14(3), 507\u2013514 (2013). https:\/\/doi.org\/10.1007\/s10198-012-0395-6","journal-title":"Eur. J. Health Econ. HEPAC Health Econ. Prev. Care"},{"key":"1122_CR56","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: Spr\u00e1vn\u00ed \u0159\u00edzen\u00ed. sp. zn. SUKLS4024\/2008 (LP Revlimid 25\u00a0mg). https:\/\/verso.sukl.cz\/fcgi\/verso.fpl?fname=vp_fspis (2008). Accessed 12 Dec 2017"},{"key":"1122_CR57","unstructured":"St\u00e1tn\u00ed \u00dastav Pro Kontrolu L\u00e9\u010div: Spr\u00e1vn\u00ed \u0159\u00edzen\u00ed. sp. zn. SUKLS109735\/2014 (LP Revlimid). https:\/\/verso.sukl.cz\/fcgi\/verso.fpl?fname=vp_fspis (2014). Accessed 12 Dec 2017"},{"key":"1122_CR58","unstructured":"National Institute for Health and Care Excellence: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. Technology appraisal guidance [TA394]. https:\/\/www.nice.org.uk\/guidance\/ta394\/chapter\/1-Recommendations (2016). Accessed 13 Dec 2017"},{"key":"1122_CR59","unstructured":"Davis, S.: NICE decision support unit methods development. In: Assessing Technologies That Are Not Cost-Effective at a Zero Price. National Institute for Health and Care Excellence (NICE), London (2014)"},{"issue":"11","key":"1122_CR60","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/11599390-000000000-00000","volume":"30","author":"DT Grima","year":"2012","unstructured":"Grima, D.T., Bernard, L.M., Dunn, E.S., McFarlane, P.A., Mendelssohn, D.C.: Cost-effectiveness analysis of therapies for chronic kidney disease patients on dialysis: a case for excluding dialysis costs. PharmacoEconomics 30(11), 981\u2013989 (2012). https:\/\/doi.org\/10.2165\/11599390-000000000-00000","journal-title":"PharmacoEconomics"},{"key":"1122_CR61","unstructured":"National Institute for Health and Care Excellence: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance [TA117]. https:\/\/www.nice.org.uk\/guidance\/ta117\/chapter\/4-Evidence-and-interpretation#cost-effectiveness (2007). Accessed 22 Jan 2018"},{"key":"1122_CR62","doi-asserted-by":"crossref","unstructured":"Maisnar V, Stefanikova Z, Spicka I, Pour L, Minarik J, Flochova E, et al. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma\u2014analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. Neoplasma (2019)","DOI":"10.4149\/neo_2018_180824N644"}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10198-019-01122-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-019-01122-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T02:39:45Z","timestamp":1664764785000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10198-019-01122-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["1122"],"URL":"https:\/\/doi.org\/10.1007\/s10198-019-01122-6","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"value":"1618-7598","type":"print"},{"value":"1618-7601","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"27 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"M Campioni is an employee of Amgen and owns stock in Amgen. I Agirrezabal was an employee of Amgen at the time of the analysis and the manuscript development. R Hajek has received research funding from Amgen, Takeda, Novartis and Janssen; consultancy fees from Amgen, Celgene, Takeda, Bristol-Myers Squibb and Janssen; and honoraria from Amgen, Celgene, Takeda, Bristol-Myers Squibb and Janssen. J Minarik and L Pour declare that they have no conflict of interest. I Spicka has received research funding from Celgene; and honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, Novartis and Takeda. S Gonzalez-McQuire is an employee of Amgen and owns stock in Amgen. P Jandova is an employee of Amgen and owns stock in Amgen. V Maisnar has received research funding from The Binding Site; worked as consultant for Amgen, Bristol-Myers Squibb, Celgene and Takeda; and received honoraria from Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}